Literature DB >> 21256901

Metallochelating liposomes with associated lipophilised norAbuMDP as biocompatible platform for construction of vaccines with recombinant His-tagged antigens: preparation, structural study and immune response towards rHsp90.

Josef Mašek1, Eliška Bartheldyová, Pavlína Turánek-Knotigová, Michaela Skrabalová, Zina Korvasová, Jana Plocková, Stěpán Koudelka, Petra Skodová, Pavel Kulich, Michal Křupka, Kateřina Zachová, Lýdie Czerneková, Milada Horynová, Irena Kratochvílová, Andrew D Miller, Daniel Zýka, Jaroslav Michálek, Jana Vrbková, Marek Sebela, Miroslav Ledvina, Milan Raška, Jaroslav Turánek.   

Abstract

Hsp90-CA is present in cell wall of Candida pseudohyphae or hyphae-typical pathogenic morphotype for both systemic and mucosal Candida infections. Heat shock protein from Candida albicans (hsp90-CA) is an important target for protective antibodies during disseminated candidiasis of experimental mice and human. His-tagged protein rHsp90 was prepared and used as the antigen for preparation of experimental recombinant liposomal vaccine. Nickel-chelating liposomes (the size around 100nm, PDI≤0.1) were prepared from the mixture of egg phosphatidyl choline and nickel-chelating lipid DOGS-NTA-Ni (molar ratio 95:5%) by hydration of lipid film and extrusion methods. New non-pyrogenic hydrophobised derivative of MDP (C18-O-6-norAbuMDP) was incorporated into liposomes as adjuvans. rHsp90 was attached onto the surface of metallochelating liposomes by metallochelating bond and the structure of these proteoliposomes was studied by dynamic light scattering, AF microscopy, TEM and GPC. The liposomes with surface-exposed C18-O-6-norAbuMDP were well recognised and phagocyted by human dendritic cells in vitro. In vivo the immune response towards this experimental vaccine applied in mice (i.d.) demonstrated both TH1 and TH2 response comparable to FCA, but without any side effects. Metallochelating liposomes with lipophilic derivatives of muramyl dipeptide represent a new biocompatible platform for construction of experimental recombinant vaccines and drug-targeting systems.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21256901     DOI: 10.1016/j.jconrel.2011.01.016

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  17 in total

Review 1.  Liposomes as vaccine delivery systems: a review of the recent advances.

Authors:  Reto A Schwendener
Journal:  Ther Adv Vaccines       Date:  2014-11

Review 2.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

Authors:  Douglas S Watson; Aaron N Endsley; Leaf Huang
Journal:  Vaccine       Date:  2012-02-02       Impact factor: 3.641

3.  Molecular adjuvants based on nonpyrogenic lipophilic derivatives of norAbuMDP/GMDP formulated in nanoliposomes: stimulation of innate and adaptive immunity.

Authors:  Pavlína Turánek Knotigová; Daniel Zyka; Josef Mašek; Anna Kovalová; Michal Křupka; Eliška Bartheldyová; Pavel Kulich; Štěpán Koudelka; Róbert Lukáč; Zuzana Kauerová; Antonín Vacek; Milada Stuchlová Horynová; Alois Kozubík; Andrew D Miller; Ladislav Fekete; Irena Kratochvílová; Jan Ježek; Miroslav Ledvina; Milan Raška; Jaroslav Turánek
Journal:  Pharm Res       Date:  2015-01-30       Impact factor: 4.200

4.  In vitro and in vivo assessment of targeting lipid-based nanoparticles to the epidermal growth factor-receptor (EGFR) using a novel Heptameric ZEGFR domain.

Authors:  S Rahima Benhabbour; J Christopher Luft; Dongwook Kim; Anekant Jain; Saurabh Wadhwa; Matthew C Parrott; Rihe Liu; Joseph M DeSimone; Russell J Mumper
Journal:  J Control Release       Date:  2011-10-20       Impact factor: 9.776

5.  Theoretical and experimental study of the antifreeze protein AFP752, trehalose and dimethyl sulfoxide cryoprotection mechanism: correlation with cryopreserved cell viability.

Authors:  Irena Kratochvílová; Martin Golan; Karel Pomeisl; Jan Richter; Silvia Sedláková; Jakub Šebera; Júlia Mičová; Martin Falk; Iva Falková; David Řeha; K Wade Elliott; Krisztina Varga; Shelby E Follett; Daniel Šimek
Journal:  RSC Adv       Date:  2016-12-23       Impact factor: 3.361

6.  Design of lipid nanocapsule delivery vehicles for multivalent display of recombinant Env trimers in HIV vaccination.

Authors:  Sharmila Pejawar-Gaddy; James M Kovacs; Dan H Barouch; Bing Chen; Darrell J Irvine
Journal:  Bioconjug Chem       Date:  2014-07-14       Impact factor: 4.774

Review 7.  Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines.

Authors:  Luis O De Serrano; David J Burkhart
Journal:  J Nanobiotechnology       Date:  2017-11-17       Impact factor: 10.435

8.  The Position of His-Tag in Recombinant OspC and Application of Various Adjuvants Affects the Intensity and Quality of Specific Antibody Response after Immunization of Experimental Mice.

Authors:  Michal Krupka; Josef Masek; Lucia Barkocziova; Pavlina Turanek Knotigova; Pavel Kulich; Jana Plockova; Robert Lukac; Eliska Bartheldyova; Stepan Koudelka; Radka Chaloupkova; Marek Sebela; Daniel Zyka; Ladislav Droz; Roman Effenberg; Miroslav Ledvina; Andrew D Miller; Jaroslav Turanek; Milan Raska
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

Review 9.  The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases.

Authors:  Roberto Nisini; Noemi Poerio; Sabrina Mariotti; Federica De Santis; Maurizio Fraziano
Journal:  Front Immunol       Date:  2018-02-05       Impact factor: 7.561

10.  AFM Monitoring the Influence of Selected Cryoprotectants on Regeneration of Cryopreserved Cells Mechanical Properties.

Authors:  Martin Golan; Sarka Jelinkova; Irena Kratochvílová; Petr Skládal; Martin Pešl; Vladimír Rotrekl; Jan Pribyl
Journal:  Front Physiol       Date:  2018-06-29       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.